Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 14/20 | 0.74 |
| ▸ | MMP8 | P22894 | 5/20 | 0.74 |
| ▸ | MMP13 | P45452 | 1/20 | 0.74 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.74 |
| ▸ | MMP2 | P08253 | 14/20 | 0.63 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | MMP12 | P39900 | 4/20 | 0.55 |
| ▸ | MMP14 | P50281 | 4/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7098598 | 1.00 | MMP9 (0.74) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL30444283 | 0.89 | MMP9 (0.60) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL4830195 | 0.88 | MMP2 (0.65) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL8839469 | 0.87 | MMP2 (0.61) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL8839475 | 0.87 | MMP2 (0.61) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL716323 | 0.86 | MMP9 (0.86) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL698930 | 0.86 | MMP9 (0.86) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL698929 | 0.86 | MMP9 (0.86) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL5875639 | 0.85 | MMP2 (0.60) | MMP9MMP8MMP13ADAMTS4MMP2 | |
| SCHEMBL14602271 | 0.85 | MMP9 (1.00) | MMP9MMP8MMP13ADAMTS4MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296551-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | DAIICHI SANKYO CO LTD (JP) | 2013-11-07 | — | — | US | disclosed |
| EP-2463268-B1 | 4-(Aminomethyl)benzoic acids as intermediates for the preparation of chymase inhibiting 1,4-diazepan-2,5-dione compounds | DAIICHI SANKYO CO LTD (JP) | 2013-08-28 | — | — | EP | disclosed |
| US-8507714-B2 | 7-membered ring compound and method of production and pharmaceutical application thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-08-13 | — | — | US | disclosed |
| EP-1820798-B1 | 7-MEMBERED RING COMPOUND, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | DAIICHI SANKYO CO LTD (JP) | 2012-08-22 | — | — | EP | disclosed |
| EP-2463268-A1 | Aminomethyl-substituted aromatic acids as intermediates for the preparation of chymase inhibiting 1,4-diazepan-2,5-dione compounds | Daiichi Sankyo Company, Limited (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20090253683-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | ASUBIO PHARMA CO., LTD (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090111796-A1 | 7-membered ring compound and method of production and pharmaceutical application thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-2025672-A1 | SEVEN-MEMBERED RING COMPOUND, PRODUCTION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | Asubio Pharma Co., Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| EP-1820798-A1 | 7-MEMBERED RING COMPOUND, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | Asubio Pharma Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111796-A1 | 7-membered ring compound and method of production and pharmaceutical application thereof | CMA1, CPA3, SI | MMP9 62/4885MMP8 57/4885MMP13 44/4885 |
| US-20130296551-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | CMA1, CPA3, SI | MMP9 62/4885MMP8 57/4885MMP13 44/4885 |
| US-20090253683-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | CMA1, CPA3, SI | MMP9 62/4885MMP8 57/4885MMP13 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.